Otezla: payments to doctors
Payments that named Otezla as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $50.6M
- Providers
- 96,853
- Transactions
- 787,134
- Average per transaction
- $64
The per-transaction average — $64 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 96,853 providers the average total is $523, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Amgen | $41,163,359 | 81.3% |
| Bristol Myers Squibb | $9,467,658 | 18.7% |
| E.r. Squibb & Sons, L.L.C. | $232 | 0.0% |